Zai Lab Limited

XNASHealth care

Last traded price · USD

$22.80

+3.83%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 03:42 IST · A quote does not mean the product is available to trade on your account.

Day's open: $23.17
Previous close: $21.96
Volume: 1.2M
Day's high: $23.40
Day's low: $22.26

In brief

Zai Lab Limited is a health care company listed on Nasdaq, valued at about $2.83B.
Its shares closed at $22.80 on 4 Nov 2026, down 11.9% over the past year.
From India you can buy ZLAB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Zai Lab Limited (ZLAB) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ZLAB share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ZLAB options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −10.9% (SPY −1.6%, XLV +13.5%). 3 months: +24.1% (SPY −0.4%, XLV +15.5%). 1 year: −11.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ZLAB, SPY and XLV · as of 4 Nov 2026
11.3 days to cover short interest
8.8M shares were sold short at the 15 Oct 2026 settlement, 7.8% of the 113.8M shares outstanding; covering them would take 11.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.7× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 2.5M shares was 2.7× the average of the 30 sessions before it (927.0K), as the price rose 1.4%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $22.80 was 7.7% below its 50-day average ($24.71) and 8.4% above its 200-day average ($21.03). It has closed above the 200-day for 64 sessions, since 6 Aug 2026. The 50-day average crossed above the 200-day on 17 Aug 2026, 56 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
59% of the way up its 52-week range
Closed at $22.80 on 4 Nov 2026: 17.1% below the 52-week high of $27.50 (2 Sep 2026) and 42.9% above the low of $15.96 (2 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−10.9%

6 months+8.5%

1 year−11.9%

5 years−77.8%

Newswire

About

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

Website

Notable moves

May 9, 2024
+26.80%
January 5, 2023
+41.80%
November 11, 2022
+24.25%

Newswire

About

Website

Notable moves

May 9, 2024
+26.80%
January 5, 2023
+41.80%
November 11, 2022
+24.25%

Zai Lab Limited

XNASHealth care

Last traded price · USD

$22.80

+3.83%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 03:42 IST · A quote does not mean the product is available to trade on your account.

Day's open: $23.17
Previous close: $21.96
Volume: 1.2M
Day's high: $23.40
Day's low: $22.26

In brief

Zai Lab Limited is a health care company listed on Nasdaq, valued at about $2.83B.
Its shares closed at $22.80 on 4 Nov 2026, down 11.9% over the past year.
From India you can buy ZLAB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Zai Lab Limited (ZLAB) shares from India?

Do I need the price of a whole ZLAB share to invest?

How much can I invest in US stocks in a year?

Can I trade ZLAB options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −10.9% (SPY −1.6%, XLV +13.5%). 3 months: +24.1% (SPY −0.4%, XLV +15.5%). 1 year: −11.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ZLAB, SPY and XLV · as of 4 Nov 2026
11.3 days to cover short interest
8.8M shares were sold short at the 15 Oct 2026 settlement, 7.8% of the 113.8M shares outstanding; covering them would take 11.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.7× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 2.5M shares was 2.7× the average of the 30 sessions before it (927.0K), as the price rose 1.4%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $22.80 was 7.7% below its 50-day average ($24.71) and 8.4% above its 200-day average ($21.03). It has closed above the 200-day for 64 sessions, since 6 Aug 2026. The 50-day average crossed above the 200-day on 17 Aug 2026, 56 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
59% of the way up its 52-week range
Closed at $22.80 on 4 Nov 2026: 17.1% below the 52-week high of $27.50 (2 Sep 2026) and 42.9% above the low of $15.96 (2 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−10.9%

6 months+8.5%

1 year−11.9%

5 years−77.8%

Newswire

About

Website

Notable moves

May 9, 2024
+26.80%
January 5, 2023
+41.80%
November 11, 2022
+24.25%

Newswire

About

Website

Notable moves

May 9, 2024
+26.80%
January 5, 2023
+41.80%
November 11, 2022
+24.25%

Zai Lab Limited

Zai Lab Limited in brief

Behind SPY and its sector fund XLV over 1 year

11.3 days to cover short interest

Volume 2.7× its 30-session average on 3 Nov 2026

Below its 50-day average, above its 200-day

59% of the way up its 52-week range

Zai Lab Limited

Zai Lab Limited in brief

Behind SPY and its sector fund XLV over 1 year

11.3 days to cover short interest

Volume 2.7× its 30-session average on 3 Nov 2026

Below its 50-day average, above its 200-day

59% of the way up its 52-week range